key: cord-0749565-mzphdznq
authors: Li, Xin; Chan, Jacky Man-Chun; Lam, Bosco; Lung, David Christopher; Lung, Kwok-Cheung; Chow, Christina Kin-Yi; Tam, Tracey; Chiu, Kelvin Hei-Yeung; Hung, Ling-Lung; Hung, Ivan Fan-Ngai; Cheng, Vincent Chi-Chung; To, Kelvin Kai-Wang; Yuen, Kwok-Yung
title: COVID-19 mRNA vaccines delay the onset of breakthrough infections with less radiographic abnormalities
date: 2022-01-04
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab1062
sha: a0357e7f621a1848e3c1c214a70bd3a52154c922
doc_id: 749565
cord_uid: mzphdznq

This retrospective study of incoming travelers with COVID-19 showed that individuals immunized by mRNA vaccines had significantly longer post-vaccination interval (median: 30.5 days) to breakthrough infection, lower WBC and LDH on admission, and less radiographic abnormalities than those immunized by inactivated virus vaccine who paradoxically had lower respiratory viral load.

M a n u s c r i p t Background Breakthrough coronavirus disease 2019 in vaccinated individuals were increasingly reported. However, the characteristics of breakthrough infections after vaccination with different types of COVID-19 vaccines are uncertain. In this study, we analyzed the differences in breakthrough infections in individuals fully vaccinated with either inactivated or mRNA vaccines which are used in our locality. The findings may impact on our requirement and choice of the third vaccine dose to consolidate the population immunity to combat the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) variants of concern(VOCs).

This is a retrospective study on cases of breakthrough COVID-19 infections in Hong Kong SAR. All in-bound travelers arriving from overseas were requested to undergo compulsory quarantine and regular testing after arrival, and all laboratory confirmed COVID-19 cases were admitted to hospitals under the Hospital Authority(HA). Data on the demographics, travel history, vaccination history, viral strain, clinical details, radiographic findings, and laboratory tests were retrieved from the electronic records of HA and daily press release by Centre for Health Protection. The abnormal chest Xrays(CXR) were scored by two clinicians independently using the Brixia scoring system [1] , and the mean scores were used for analysis. Statistical analysis was performed using Prism 9.1.2(GraphPad Software, San Diego, CA). Numerical variables were compared using Mann-Whiney test. Categorical variables were compared using Chi-square or Fisher's exact tests. Hazard ratios were calculated using logrank test. The study was approved by the Institutional Review Board of HA (CIRB-2021-013-4). demonstrated that the risk of breakthrough infection correlated with Nab titers during the periinfection period [3] , no significant difference in the anti-RBD antibody titers was observed at the time of presentation between our two groups. One inherent problem of immune correlate is the lack of a standalone marker that can recapitulate the complex immune response to natural infection or vaccination. In non-human primate studies, vaccine-elicited ELISpot responses, and CD4+ and CD8+ intracellular cytokine staining responses, did not correlate with protection [4] . However, evidence from both human and animal studies suggested that recovery from COVID-19 requires a robust cellmediated response, including both cytotoxic CD8+ and Th1 CD4+ T cell response, probably more so than high titers of Nab [5] . T-cell immunity as measured by interferon-γ ELISpot was found comparable between convalescent COVID-19 patients with undetectable SARS-CoV-2 IgG and those with strong antibody response, suggesting that immunity may be mediated through T cells [6] .

A c c e p t e d M a n u s c r i p t Moreover, the protective role of antibody-dependent cellular cytotoxicity (ADCC) against spike or internal proteins of SARS-CoV-2 are still uncertain, though ADCC mediated by diverse epitope specificities may contribute [7] .

Despite a higher viral load in the upper respiratory tract specimen which could be related to higher virus exposure or less mucosal immunity in the mRNA vaccine group with more non-Asians, we postulated that the mRNA vaccine likely induces a more solid protection by rapid recruitment of T-cell responses and protects the patient from lung damage. Inactivated whole virion vaccines with alum adjuvant generate poor cytotoxic T-or cell-mediated immunity. These vaccine recipients generally had lower T-cell response as measured by the ELISpot method [8] . Here, though both vaccine groups had comparable antibody titer, the extent of protection differs as evident by the significantly higher percentage of radiological abnormalities and higher peripheral blood WBC and LDH in those who received the inactivated vaccine. Without adequate T-cell response, the time taken to recruit cytotoxic T cells to clear the SARS-CoV-2 breakthrough infection may be longer in those whose immune system was primed by the inactivated vaccine, thus more radiological changes of inflammation which signifies the clearance of viral infected cells at the time of presentation. Our recent study showed that the BNT162b2 mRNA vaccine induced higher Nab response and spikespecific CD4+ T cell response than the inactivated vaccine against the original SARS-CoV-2 and VOCs [9]. Studies in non-human primates also showed that the mRNA-1273 vaccine induced high levels of Th1 response with low-to undetectable Th2 response, providing high-level protection with minimal risk of vaccine-associated enhanced respiratory disease [10] . Although another study suggested that inactivated vaccine induced stronger T-cell response measured in vitro [11] , the clinical correlation is uncertain, as indiscriminatory T-cell reactivity may paradoxically induce more inflammatory damage if a longer time is needed for immune recruitment and allows more virus replication before immune control starts.

Our study suggested that mRNA vaccines offered longer protection against breakthrough infection than inactivated vaccines, as evidenced by the longer time to breakthrough after the completion of 2 doses. Besides a more robust T-cell response, the BNT162b2 mRNA vaccine was A c c e p t e d M a n u s c r i p t known to elicit strong spike-specific memory B cells that lasted at least 6 months [12] . Though the protective efficacy wanes with time, viral load control by BNT162b2 in breakthrough infection was restored after a booster dose [2] .

There are limitations of this study. First, more Asians and females were in the inactivated vaccine group with more severe pulmonary radiographic disease despite a lower viral load in upper respiratory tract secretions. However, Asian females may be more compliant with masking and therefore had lower dose of viral exposure. Moreover, COVID-19 severity should be lower in females due to innate immune and endocrine differences with males. Second, few whole genome sequencing was performed as viral loads were sometimes too low for genome analysis for viral variant. However, epidemiological evidence that the variants are associated with difference in disease severity were largely context dependent. Third, incomplete reporting of the underlying illness was possible in retrospective study. More studies on the protective efficacy of a third dose of mRNA or inactivated vaccine in individuals previously vaccinated by 2 doses of inactivated vaccine with alum adjuvant are warranted. In conclusion, although vaccine protection wanes with time, the mRNA COVID-19 vaccines appeared to provide more prolonged and solid protection against lung involvement in breakthrough infections than the inactivated vaccine. M a n u s c r i p t A c c e p t e d M a n u s c r i p t 

COVID-19 outbreak in Italy: experimental chest X-ray scoring system for quantifying and monitoring disease progression. La Radiologia medica

Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Immunological mechanisms of vaccine-induced protection against COVID-19 in humans

Convalescents with PCR-Confirmed Infection but with Undetectable SARS-CoV-2-Specific IgG. Emerg Infect Dis

Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases

Waning immune responses against SARS-CoV-2 among vaccinees in Hong Kong

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong

Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine

A c c e p t e d M a n u s c r i p t